Bicara Therapeutics (BCAX) Stock Price, News & Analysis

Company Overview

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.

Key Stats

• Today's Range: $18.28 to $18.83
• 50-Day Range: $18.38 to $27.07
• 52-Week Range: $17.62 to $28.09
• Volume: 19,483 shs
• Average Volume: 353,626 shs
• Market Capitalization: $994.80 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $43.33
• Consensus Rating: Buy

Bicara Therapeutics Stock Analysis - MarketRank™

Bicara Therapeutics scored higher than 64% of companies evaluated by MarketBeat, and ranked 360th out of 963 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.6 / 5
• Analyst Rating: Buy

Consensus Rating

Bicara Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.17, and is based on 5 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Bicara Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Bicara Therapeutics are expected to grow in the coming year, from ($2.89) to ($1.65) per share.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for BCAX.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Bicara Therapeutics does not currently pay a dividend.

Dividend Growth

Bicara Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for BCAX.

News and Social Media

• Score: 1.6 / 5
• News Sentiment: -0.06

News Sentiment

Bicara Therapeutics has a news sentiment score of -0.06. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.46 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 10 news articles for Bicara Therapeutics this week, compared to 3 articles on an average week.

MarketBeat Follows

2 people have added Bicara Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Bicara Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $34,254,000.00 in company stock and sold $0.00 in company stock.

BCAX Stock Analysis - Frequently Asked Questions

How have BCAX shares performed this year?

Bicara Therapeutics' stock was trading at $25.41 on January 1st, 2024. Since then, BCAX stock has decreased by 27.8% and is now trading at $18.35.
View the best growth stocks for 2024 here.

How were Bicara Therapeutics' earnings last quarter?

Bicara Therapeutics Inc. (NASDAQ:BCAX) posted its quarterly earnings data on Tuesday, November, 12th. The company reported ($1.60) EPS for the quarter, missing analysts' consensus estimates of ($0.46) by $1.14.

When did Bicara Therapeutics IPO?

Bicara Therapeutics (BCAX) raised $315 million in an initial public offering (IPO) on Friday, September 13th 2024. The company issued 17,500,000 shares at a price of $18.00 per share.

When did Bicara Therapeutics' quiet period expire?

Bicara Therapeutics' quiet period expired on Wednesday, October 23rd. Bicara Therapeutics had issued 17,500,000 shares in its public offering on September 13th. The total size of the offering was $315,000,000 based on an initial share price of $18.00. During Bicara Therapeutics' quiet period, insiders and any underwriters involved in the IPO were restricted from issuing any research reports for the company because of SEC regulations. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company.

Who are Bicara Therapeutics' major shareholders?

Bicara Therapeutics' top institutional shareholders include RA Capital Management L.P. (13.44%), FMR LLC (4.39%), Braidwell LP (3.20%) and Janus Henderson Group PLC (2.30%).
View institutional ownership trends.

How do I buy shares of Bicara Therapeutics?

Shares of BCAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Company Calendar

• Last Earnings: 11/12/2024
• Today: 11/21/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:BCAX
• Previous Symbol: NASDAQ:BCAX
• CUSIP: N/A
• CIK: 2023658
• Web: www.bicara.com
• Phone: (617) 468-4219
• Fax: N/A
• Employees: 32
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $43.33
• High Stock Price Target: $48.00
• Low Stock Price Target: $35.00
• Potential Upside/Downside: +135.8%
• Consensus Rating: Buy
• Rating Score (0-4): 3.17
• Research Coverage: 6 Analysts

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 54,420,000
• Free Float: N/A
• Market Cap: $1.00 billion
• Optionable: N/A
• Beta: N/A